Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Allovectin-7: Phase II

Interim data from a U.S. Phase II trial showed 12 of 91 (13%)

Read the full 134 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE